A new insulin preparation reduces after-meal blood-glucose (BG) values in people with diabetes without causing hypoglycemia.
Calling the new preparation hepatic directed vesicle-insulin (HDV-insulin), researchers at Vanderbilt University are suggesting it may “prove to be more suitable than Regular insulin for aggressive therapy,” according to a September 28 Reuters Health report.
In the September/October issue of the Journal of Diabetes and Its Complications, Stephen N. Davis, MD, and colleagues call the advantages of HDV-insulin “two-fold,” saying that insulin directed at the liver should suppress the output of glucose by that organ while increasing its ability to metabolize glucose. Also, they said, improved post-meal blood-glucose levels can be obtained with reduced insulin circulating in the bloodstream.
The investigators note that adding a molecule that targets the liver to a soluble pouch designed to deliver insulin created HPV-insulin. According to Reuters, the effects of a single injection of HDV-insulin or Regular insulin administered 30 minutes before a 75-gram oral glucose tolerance test in nine patients with type 1 diabetes were observed. Each subject received the opposite type of insulin in an identical protocol four weeks later.
HDV-insulin lowered glucose levels 39.6 mg/dl during the test compared with Regular insulin.
“Plasma levels of insulin and glucagon were equivalent during both series of experiments,” according to the paper.